Commentary
Video
Author(s):
E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses prognosis and rarity of patients with NRG1 fusion–positive pancreatic cancer.
NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers
Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH
Tumor Treating Fields Plus Chemotherapy Improves OS in Unresectable Pancreatic Cancer
Park and Grivas Expand on Treatment Updates in Bladder Cancer
Targeted Therapies Remain Central to Ongoing Research in Pancreatic Cancer
Pancreatic Cancer Awareness Month Brings Attention to Growing Incidence and Treatment Advances
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS